The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Open accessAbstract
The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”
From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Ding et al., 2012
In the citing paper
“For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy 9.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationTumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citationWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citationCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489
Cited by
Sorted by citations
Items 901–999 of 999
The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells
Balça-Silva, J., Matias, D., Dubois, L. G., Carneiro, B., do Carmo, A., Girão, H., Ferreira, F. L., Ferrer, V. P., Chimelli, L. M. C., Filho, P. N., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.04.005 · Cited by 26
Xing, X., Jia, S., Wu, J., Feng, Q. F., Dong, B., Li, B., Jia, Y., Shan, F., Li, Y., Zhang, Y., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4932 · Cited by 25
Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features
Zhou, F., & Chen, B. (2018) · Hematology · doi:10.1080/10245332.2018.1482051 · Cited by 25
Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells
Tong, M., Deng, Z., Yang, M., Xu, C., Zhang, X., Zhang, Q., Liao, Y., Deng, X., Lv, D., Zhang, X., et al. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0326-8 · Cited by 25
Tavor, S., Shalit, T., Chapal-Ilani, N., Moskovitz, Y., Livnat, N., Groner, Y., Barr, H. M., Minden, M. D., Plotnikov, A. N., Deininger, M. W., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240705 · Cited by 25
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., & Yakoub‐Agha, I. (2021) · Cancers · doi:10.3390/cancers13246157 · Cited by 25
Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment
Banella, C., Catalano, G., Travaglini, S., Pelosi, E., Ottone, T., Zaza, A., Guerrera, G., Angelini, D. F., Niscola, P., Divona, M., et al. (2022) · Cancers · doi:10.3390/cancers14102565 · Cited by 26
Bayesian Inference for Intratumour Heterogeneity in Mutations and Copy Number Variation
Lee, J., Müller, P., Sengupta, S., Gulukota, K., & Ji, Y. (2016) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/rssc.12136 · Cited by 25
Malmberg, E. D., Rehammar, A., Pereira, M. B., Abrahamsson, J., Samuelsson, T., Ståhlman, S., Asp, J., Tierens, A. M., Palmqvist, L., Kristiansson, E., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.08.004 · Cited by 25
Madonna, M. C., Fox, D. B., Crouch, B. T., Lee, J., Zhu, C., Martinez, A. F., Alvarez, J. V., & Ramanujam, N. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0618 · Cited by 25
Paolino, G., Corsetti, P., Moliterni, E., Corsetti, S., Didona, D., Albanesi, M., Mattozzi, C., Lido, P., & Calvieri, S. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.17.05818-7 · Cited by 27
Zhou, J., Liu, Y., Zhang, Y., Li, Q., & Cao, Y. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1940 · Cited by 25
HeLa-CCL2 cell heterogeneity studied by single-cell DNA and RNA sequencing
Hu, W., Zhang, X., Guo, Q., Yang, J., Yang, Y.-A., Wei, S., & Su, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225466 · Cited by 25
BERNASCONI, P. P., & Borsani, O. (2019) · Cancers · doi:10.3390/cancers12010069 · Cited by 25
Next-generation sequencing in hematologic malignancies: what will be the dividends?
Merker, J. D., Valouev, A., & Gotlib, J. R. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712458948 · Cited by 26
Cancer stem cells modulate patterns and processes of evolution in cancers
Laplane, L. (2018) · Biology & Philosophy · doi:10.1007/s10539-018-9629-z · Cited by 26
Kim, T., Yoshida, K., Kim, Y. K., Tyndel, M. S., Park, H. J., Choi, S., Ahn, J., Jung, S.-H., Yang, D.-H., Lee, J.-J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.264 · Cited by 24
Should persons with acute myeloid leukemia have a transplant in first remission?
Gale, R. P., Wiernik, P. H., & Lazarus, H. M. (2014) · Leukemia · doi:10.1038/leu.2014.129 · Cited by 24
Genome variation and personalized cancer medicine
Hudson, T. J. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12097 · Cited by 25
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations
Weigelt, B., Reis-Filho, J. S., & Swanton, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds323 · Cited by 24
Bera, R., Chiu, M.-C., Huang, Y., Liang, D., Lee, Y., & Shih, L. (2018) · Neoplasia · doi:10.1016/j.neo.2018.08.013 · Cited by 27
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy
Qian, J., Xu, J., Wang, S., Qian, F., Yang, W., Zhang, B., Zhang, Y., Nie, W., Lou, Y., Lü, J., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07366-z · Cited by 24
Vu, M., Kassouf, N., Ofili, R., Lund, T., Bell, C., & Appiah, S. S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5052 · Cited by 24
Marensi, V., Keeshan, K., & MacEwan, D. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114348 · Cited by 23
Gawin, M., Kurczyk, A., Niemiec, J. A., Stanek‐Widera, A., Grela-Wojewoda, A., Adamczyk, A., Biskup-Frużyńska, M., Polańska, J., & Widłak, P. (2021) · Cancers · doi:10.3390/cancers13174349 · Cited by 24
Leukemia’s Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy
Zoine, J. T., Moore, S. E., & Velasquez, M. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867103 · Cited by 24
Caught in the act—Visualizing ribonucleases during eukaryotic ribosome assembly
Schneider, C., & Bohnsack, K. E. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1766 · Cited by 24
Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells
Costa, R. G. A., Silva, S. L. R., Dias, I. R. S. B., Oliveira, M. D. S., Rodrigues, A. C., Dias, R. B., & Bezerra, D. P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102692 · Cited by 25
Zhang, J., Duan, Y.-J., Wu, P., Chang, Y., Wang, Y., Hu, T., Liu, C., Chen, X., Zong, S.-Y., Chen, X., et al. (2023) · Blood · doi:10.1182/blood.2023020490 · Cited by 28
Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity
Zoine, J. T., Immadisetty, K., Ibañez-Vega, J., Moore, S. E., Nevitt, C. D., Thanekar, U., Tian, L., Karouni, A., Chockley, P. J., Arthur, B., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101422 · Cited by 24
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
Chesnais, V., Kosmider, O., Damm, F., Itzykson, R., Bernard, O., Solary, É., & Fontenay, M. (2012) · Oncotarget · doi:10.18632/oncotarget.749 · Cited by 25
van Wezel, E. M., Zwijnenburg, D. A., Zappeij‐Kannegieter, L., Bus, E. W. N., van Noesel, M. M., Molenaar, J. J., Versteeg, R., Fiocco, M. F., Caron, H. N., van der Schoot, C. E., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.09.005 · Cited by 24
MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
Verboon, L., Obulkasim, A., de Rooij, J. D. E., Katsman-Kuipers, J. E., Sonneveld, E., Baruchel, A., Trka, J., Reinhardt, D., Pieters, R., Cloos, J. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10270 · Cited by 24
Evolutionary trajectory of leukemic clones and its clinical implications
Tuval, A., & Shlush, L. I. (2019) · Haematologica · doi:10.3324/haematol.2018.195289 · Cited by 28
Klijn, C. N., Koudijs, M. J., Kool, J., ten Hoeve, J., Boer, M., de Moes, J., Akhtar, W., van Miltenburg, M., Vendel-Zwaagstra, A., Reinders, M. J. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062113 · Cited by 24
Intratumor Heterogeneity and Branched Evolution
Bambury, R. M., Power, D. G., & O’Reilly, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1204069 · Cited by 24
Acute Myeloid Leukemia — Many Diseases, Many Treatments
Estey, E. H. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611424 · Cited by 24
Genomic tools in acute myeloid leukemia: From the bench to the bedside
White, B. S., & DiPersio, J. F. (2014) · Cancer · doi:10.1002/cncr.28552 · Cited by 23
Aldehyde dehydrogenases in acute myeloid leukemia
Smith, C. A., Gasparetto, M., Humphries, R. K., Pollyea, D. A., Vasiliou, V., & Jordan, C. T. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12414 · Cited by 23
Govindan, R. (2014) · Science · doi:10.1126/science.1259926 · Cited by 23
Barøy, T., Chilamakuri, C. S. R., Lorenz, S., Sun, J., Bruland, Ø. S., Myklebost, O., & Meza‐Zepeda, L. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163859 · Cited by 22
Al-Dewik, N. I. E., Tawfeg, B.-O., Zayed, H., Trujillano, D., Kishore, S., Rolfs, A., & Yassin, M. A. (2018) · Gene · doi:10.1016/j.gene.2018.12.009 · Cited by 22
Precision oncology: lessons learned and challenges for the future
Yang, H., Shah, R. H., Tegay, D. H., & Onel, K. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201326 · Cited by 25
Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells
Cornet-Masana, J. M., Banús‐Mulet, A., Carbo, J. M. C. I., Torrente, M. Á., Guijarro, F., Cuesta‐Casanovas, L., Esteve, J., & Risueño, R. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.021 · Cited by 23
Nuclear RNA Exosome and Pervasive Transcription: Dual Sculptors of Genome Function
Ogami, K., & Suzuki, H. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413401 · Cited by 24
Cancer networks and beyond: Interpreting mutations using the human interactome and protein structure
Gulati, S., Cheng, T. M. K., & Bates, P. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.002 · Cited by 23
Parker, W. T., Yeoman, A. L., Jamison, B. A., Yeung, D. T. O., Scott, H. S., Hughes, T. P., & Branford, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.318 · Cited by 23
Environmental-stress-induced Chromatin Regulation and its Heritability
Fang, K. W. L. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000156 · Cited by 24
AML evolution from preleukemia to leukemia and relapse
Shlush, L. I., & Mitchell, A. (2015) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2015.10.004 · Cited by 23
A mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity
Fuentes‐Garí, M., Misener, R., Munzer, D. G., Velliou, E. G., Georgiadis, M. C., Kostoglou, M., Pistikopoulos, E. N., Panoskaltsis, N., & Mantalaris, A. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2015.0276 · Cited by 25
The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia
Tremblay, C. S., & Curtis, D. J. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000058 · Cited by 24
Structural Prediction of Protein–Protein Interactions by Docking: Application to Biomedical Problems
Barradas‐Bautista, D., Rosell, M., Pallara, C., & Fernández‐Recio, J. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.06.003 · Cited by 24
Kim, S., Kim, S., Kim, J., Kim, B., Kim, S. I., Kim, M. A., Kwon, S., & Song, Y. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-31097-y · Cited by 23
Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity
Ferrall‐Fairbanks, M. C., Ball, M., Padron, E., & Altrock, P. M. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00074 · Cited by 22
Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Goswami, M., & Hourigan, C. S. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223120005 · Cited by 23
The complexity of interpreting genomic data in patients with acute myeloid leukemia
Nazha, A., Zarzour, A., Al-Issa, K., Radivoyevitch, T., Carraway, H. E., Hirsch, C. M., Przychodzen, B. P., Patel, B. J., Clemente, M. J., Sanikommu, S. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.115 · Cited by 23
Mutation Position Within Evolutionary Subclonal Architecture in AML
Welch, J. S. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.004 · Cited by 25
Molecular targets on the horizon for kidney and urothelial cancer
Joaquim Bellmunt, B., Teh, B. T., Tortora, G., & Rosenberg, J. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.155 · Cited by 24
Whole genome sequencing as a means to assess pathogenic mutations in medical genetics and cancer
Royer‐Bertrand, B., & Rivolta, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1807-9 · Cited by 23
Zuffa, E., Franchini, E., Papayannidis, C., Baldazzi, C., Simonetti, G., Testoni, N., Abbenante, M. C., Paolini, S., Sartor, C., Parisi, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5161 · Cited by 23
Three patients with DeSanto‐Shinawi syndrome: Further phenotypic delineation
Uehara, T., Ishige, T., Hattori, S., Yoshihashi, H., Funato, M., Yamaguchi, Y., Takenouchi, T., & Kosaki, K. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38703 · Cited by 23
Data mining for mutation-specific targets in acute myeloid leukemia
Benard, B. A., Gentles, A. J., Köhnke, T., Majeti, R., & Thomas, D. (2019) · Leukemia · doi:10.1038/s41375-019-0387-y · Cited by 23
Roussel, X., Daguindau, É., Berceanu, A., Desbrosses, Y., Warda, W., Rocha, M. N. D., Trad, R., Deconinck, É., Deschamps, M., & Ferrand, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599933 · Cited by 24
Dissecting Clonal Heterogeneity in AML
Schuringa, J. J., & Bonifer, C. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.011 · Cited by 23
Loke, J. C. T., Vyas, H., & Craddock, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666091 · Cited by 22
Menssen, A. J., Khanna, A., Miller, C. A., Srivatsan, S. N., Chang, G. S., Shao, J., Robinson, J., O’Laughlin, M., Fronick, C. C., Fulton, R. S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0155 · Cited by 23
Jun, S.-H., Toosi, H., Mold, J. E., Engblom, C., Chen, X., O’Flanagan, C. H., Hagemann-Jensen, M., Sandberg, R., Aparicio, S. A. J. R., Hartman, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36202-y · Cited by 23
Filipek-Gorzała, J., Kwiecińska, P., Szade, A., & Szade, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1308709 · Cited by 24
Genome instability mechanisms and the structure of cancer genomes
Cassidy, L. D., & Venkitaraman, A. R. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.003 · Cited by 22
Cancer heterogeneity determined by functional proteomics
Szász, A. M., Győrffy, B., & Marko‐Varga, G. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.026 · Cited by 22
The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Buccisano, F., Hourigan, C. S., & Walter, R. B. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0420-z · Cited by 22
FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist
Assi, R. E., & Ravandi, F. (2017) · American Journal of Hematology · doi:10.1002/ajh.25027 · Cited by 21
Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy
Fiedler, E. C., & Hemann, M. T. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055524 · Cited by 22
Harada, K., Okamoto, W., Mimaki, S., Kawamoto, Y., Bando, H., Yamashita, R., Yuki, S., Yoshino, T., Komatsu, Y., Ohtsu, A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5479-6 · Cited by 23
Qin, K., Jian, D., Xue, Y., Cheng, Y., Zhang, P., Wei, Y., Zhang, J., Xiong, H., Zhang, Y., & Yuan, X. (2021) · Oncology Reports · doi:10.3892/or.2021.7951 · Cited by 20
Epigenetic Mechanisms in Leukemias and LymphomasPreprint
Duy, C., Béguelin, W., & Melnick, A. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034959 · Cited by 23
Smith, M. L., & McKerrell, T. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch3 · Cited by 22
Boutzen, H., Murison, A., Oriecuia, A., Bansal, S., Arlidge, C., Wang, J. C. Y., Lupien, M., Kaufmann, K. B., & Dick, J. E. (2024) · Leukemia · doi:10.1038/s41375-024-02358-9 · Cited by 24
Clonal expansion dictates the efficacy of mitochondrial lineage tracing in single cells
Wang, X., Wang, K., Zhang, W., Tang, Z., Zhang, H., Cheng, Y., Zhou, D., Zhang, C., Zhong, W., Ma, Q., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03540-7 · Cited by 21
Determination of ETV 6‐ RUNX 1 genomic breakpoint by next‐generation sequencing
Jin, Y., Wang, X., Hu, S., Tang, J., Li, B., & Chai, Y.-H. (2015) · Cancer Medicine · doi:10.1002/cam4.579 · Cited by 21
Bulk Genotyping of Biopsies Can Create Spurious Evidence for Hetereogeneity in Mutation Content
Kostadinov, R. L., Maley, C. C., & Kuhner, M. K. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004413 · Cited by 20
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl, M. F., Lu, B. Y., Kim, T. K., & Zeidan, A. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0503-8 · Cited by 22
Jentzsch, M., Bill, M., Grimm, J., Schulz, J. C., Goldmann, K., Beinicke, S., Häntschel, J., Pönisch, W., Franke, G., Vučinić, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21322 · Cited by 21
Jentzsch, M., Bill, M., Grimm, J., Schulz, J. C., Beinicke, S., Häntschel, J., Goldmann, K., Pönisch, W., Franke, G., Vučinić, V., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000167 · Cited by 21
Trace the profile and function of circular RNAs in Sertoli cell only syndrome
Zhu, F., Luo, Y., Bo, H., Gong, G., Tang, R., Fan, J., Zhang, H., Liu, G., Zhu, W., Tan, Y., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.04.022 · Cited by 21
Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies
Debek, S. M., & Juszczyński, P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188697 · Cited by 23
Metabolic crosstalk between stromal and malignant cells in the bone marrow niche
Tirado, H. A., Balasundaram, N., Laaouimir, L., Erdem, A., & van Gastel, N. (2023) · Bone Reports · doi:10.1016/j.bonr.2023.101669 · Cited by 25
Clonal evolution and tumor-initiating cells: New dimensions in cancer patient treatment
Apostoli, A. J., & Ailles, L. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1083944 · Cited by 21
The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias
Testa, U., & Pelosi, E. (2013) · Leukemia Research and Treatment · doi:10.1155/2013/275760 · Cited by 23
Variation in Dicer Gene Is Associated with Increased Survival in T-Cell Lymphoma
Li, X., Tian, X., Zhang, B., Zhang, Y., & Chen, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051640 · Cited by 21
Karjalainen, E., & Repasky, G. A. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.005 · Cited by 23
van Strijp, D., Vulders, R. C. M., Larsen, N. A., Schira, J., Bærlocher, L., van Driel, M. A., Pødenphant, M., Hansen, T. S., Kristensen, A. S., Mir, K. U., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10704-4 · Cited by 21
The evolving role of next generation sequencing in myelodysplastic syndromes
Spaulding, T. P., Stockton, S. S., & Savona, M. R. (2019) · British Journal of Haematology · doi:10.1111/bjh.16212 · Cited by 21
Clonal evolution and immune evasion in posttransplantation relapses
Vago, L. (2019) · Hematology · doi:10.1182/hematology.2019000005 · Cited by 21
Novel Approaches to Target Mutant FLT3 Leukaemia
Müller, J. P., & Schmidt‐Arras, D. (2020) · Cancers · doi:10.3390/cancers12102806 · Cited by 21
To portray clonal evolution in blood cancer, count your stem cells
Lyne, A.-M., Laplane, L., & Perié, L. (2020) · Blood · doi:10.1182/blood.2020008407 · Cited by 26
Faulk, K. E., Gore, L., & Cooper, T. M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0067-3 · Cited by 23
Górniak, P., Ejduk, A., Borg, K., Makuch‐Łasica, H., Nowak, G., Lech‐Marańda, E., Prochorec‐Sobieszek, M., Warzocha, K., & Juszczyński, P. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12566 · Cited by 22
Metadata
- Authors
- Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Ley, Timothy J.
- ORCID
- Ding, Li
- Ley, Timothy J.
- Larson, David E.
- Miller, Christopher A.
- Koboldt, Daniel C.
- Welch, John S.
- Ritchey, Julie K.
- McLellan, Michael D.
- McMichael, Joshua F.
- Lu, Charles
- Shen, Dong
- Fulton, Robert S.
- Fulton, Lucinda L.
- Chen, Ken
- Magrini, Vincent J.
- McGrath, Sean D.
- Vickery, Tammi L.
- Wendl, Michael C.
- Heath, Sharon
- Watson, Mark A.
- Link, Daniel C.
- Tomasson, Michael H.
- Payton, Jacqueline E.
- Kulkarni, Shashikant
- Walter, Matthew J.
- Graubert, Timothy A.
- Mardis, Elaine R.
- Wilson, Richard K.
- DiPersio, John F.
- Venue
- Nature
- Published
- 2012-01
- Volume
- 481
- Issue
- 7382
- Pages
- 506-510
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3267864
- OpenAlex
- W2093144236
- Cited by
- 1,993
- References
- 30
- Citations by year
- 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
- FWCI
- 149.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Foundation for Barnes-Jewish Hospital (00335-0505-02)
- National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
- National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
- MeSH terms
- Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
